MorphoSys's MOR103 Antibody Demonstrates Excellent Safety and Efficacy in Rheumatoid Arthritis Patients
www.morphosys.com/sites/default/files...

MorphoSys to Host Conference Call on Clinical Trial Results of MOR103 in Rheumatoid Arthritis
09/21/2012 - Conference Call and Webcast: Clinical Trial Results of MOR103 in Rheumatoid Arthritis
Today at 3:00 p.m. CET (2:00 p.m. BST, 9:00 a.m. EDT), the Management Board of MorphoSys AG will host a public conference call and webcast to present information on the results of the clinical phase 1b/2a trial of MorphoSys's proprietary antibody MOR103 in patients with rheumatoid arthritis, which was announced yesterday.
www.media-server.com/m/p/wbc89y57